Valuation: Seres Therapeutics, Inc.

Market Cap 1.78Cr 1.59Cr 1.46Cr 1.33Cr 2.48Cr 168.82Cr 2.53Cr 17Cr 7.01Cr 89Cr 6.67Cr 6.53Cr 280.05Cr P/E 2026 *
-0.5x
P/E 2027 * -0.36x
Enterprise Value 1.78Cr 1.59Cr 1.46Cr 1.33Cr 2.48Cr 168.82Cr 2.53Cr 17Cr 7.01Cr 89Cr 6.67Cr 6.53Cr 280.05Cr EV / Sales 2026 *
1.29x
EV / Sales 2027 * 65x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-9.23%
1 week-15.31%
Current month-47.16%
1 month-47.16%
3 months-62.97%
6 months-75.98%
Current year-88.10%
1 week 1.68
Extreme 1.675
2.18
1 month 1.68
Extreme 1.675
3.2
Current year 1.68
Extreme 1.675
16.42
1 year 1.68
Extreme 1.675
29.98
3 years 1.68
Extreme 1.675
41
5 years 1.68
Extreme 1.675
233.8
10 years 1.68
Extreme 1.675
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
Chief Executive Officer 58 01/08/2025
President 51 02/03/2026
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-9.23%-15.31%-88.78%-93.90% 1.78Cr
-0.62%-1.87%+46.31%+56.99% 6.38TCr
+0.35%+3.20%+14.92%+84.55% 5.64TCr
+0.53%+1.96%+15.37%+106.81% 5.46TCr
-2.81%-4.31%+23.50%+50.90% 4.41TCr
-0.33%-1.93%+20.15%+98.45% 4.21TCr
+0.55%+2.31%+224.97%+942.56% 4.1TCr
+3.27%+47.96%+112.67%+96.48% 3.49TCr
+1.22%-1.44%+14.89%+47.15% 3.28TCr
+0.89%+20.55%-42.03%+373.03% 2.47TCr
Average -0.62%+5.25%+34.20%+176.30% 3.94TCr
Weighted average by Cap. +0.18%+5.44%+48.49%+186.12%

Financials

2026 *2027 *
Net sales 1.38Cr 1.24Cr 1.14Cr 1.03Cr 1.93Cr 131Cr 1.96Cr 14Cr 5.44Cr 69Cr 5.18Cr 5.07Cr 217.32Cr 3L 2L 2L 2L 4L 2.6Cr 4L 26.87L 10.79L 1.37Cr 10.26L 10.05L 4.31Cr
Net income -3.75Cr -3.36Cr -3.09Cr -2.8Cr -5.23Cr -355.95Cr -5.33Cr -37Cr -15Cr -187.24Cr -14Cr -14Cr -590.49Cr -7.9Cr -7.07Cr -6.5Cr -5.89Cr -11Cr -749.68Cr -11Cr -78Cr -31Cr -394.35Cr -30Cr -29Cr -1.24TCr
Net Debt - -
Projected Income Statement - Annual - Seres Therapeutics, Inc.
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
30/26/30 $1.770 -9.23% 1,20,110
29/26/29 $1.950 +8.94% 78,506
28/26/28 $1.790 -0.56% 87,496
27/26/27 $1.800 -9.09% 1,65,350
26/26/26 $1.980 -5.26% 53,065
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Seres Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.770USD
Average target price
17.00USD
Spread / Average Target
+860.45%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Seres Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. MCRB Stock